Savara (SVRA) Cash & Equivalents (2010 - 2026)
Savara (SVRA) recorded Cash & Equivalents of $41.8 million in Q2 2026, up 139.7% from $17.44 million a year earlier and up 7.7% from the prior quarter.
Powered by 
Analysis
Savara (SVRA) Cash & Equivalents (2010 - 2026) Analysis & Trends
At the end of FY2025, Savara reported Cash & Equivalents of $33.18 million, up 119.3% from FY2024.
- Annual Cash & Equivalents has a five-year compound annual growth rate of 7.7% (FY2020 to FY2025).
- Across earlier years, Cash & Equivalents came in at $15.13 million in FY2024 (-43.1%), $26.59 million in FY2023 (-49.0%), $52.1 million in FY2022 (+53.2%) and $34.01 million in FY2021 (+48.7%).
- The Q2 2026 figure is the highest quarterly Cash & Equivalents since Q4 2022.
- On a year-over-year basis, Cash & Equivalents has increased for three consecutive quarters, with growth averaging 32.1% over the last eight quarters.
- Peak year-over-year performance for Cash & Equivalents in the last five years was growth of 168.1% in Q3 2022, against a decline of 76.9% in Q3 2023 at the low end.
- Per Business Quant, the preceding three quarters came in at $38.8 million (Q1 2026), $33.18 million (Q4 2025) and $16.3 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,076.25 Bn | 1,044.84 Bn | 19.71 Bn | 8.95 Bn |
| 2 | Johnson & Johnson | 617.18 Bn | 535.70 Bn | 17.26 Bn | 20.42 Bn |
| 3 | AbbVie | 464.58 Bn | 437.73 Bn | 12.70 Bn | 6.57 Bn |
| 4 | Merck | 356.04 Bn | 310.47 Bn | 12.21 Bn | 6.85 Bn |
| 5 | Novartis Ag | 269.07 Bn | 224.94 Bn | 11.24 Bn | 7.62 Bn |
| 6 | Astrazeneca | 243.21 Bn | 216.77 Bn | 12.86 Bn | 4.89 Bn |
| 7 | Amgen | 217.88 Bn | 173.28 Bn | 7.24 Bn | 13.99 Bn |
| 8 | Gilead Sciences | 179.62 Bn | 153.74 Bn | 6.22 Bn | 3.18 Bn |
| 9 | Pfizer | 158.45 Bn | 105.40 Bn | 10.94 Bn | 976.00 Mn |
| 10 | Savara | 987.97 Mn | 987.97 Mn | - | 41.80 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 41.80 Mn |
| Mar 31, 2026 | 38.80 Mn |
| Dec 31, 2025 | 33.18 Mn |
| Sep 30, 2025 | 16.30 Mn |
| Jun 30, 2025 | 17.44 Mn |
| Mar 31, 2025 | 19.60 Mn |
| Dec 31, 2024 | 15.13 Mn |
| Sep 30, 2024 | 21.43 Mn |
| Jun 30, 2024 | 23.90 Mn |
| Mar 31, 2024 | 16.80 Mn |
| Dec 31, 2023 | 26.59 Mn |
| Sep 30, 2023 | 27.70 Mn |
| Jun 30, 2023 | 22.75 Mn |
| Mar 31, 2023 | 34.00 Mn |
| Dec 31, 2022 | 52.10 Mn |
| Sep 30, 2022 | 119.84 Mn |
| Jun 30, 2022 | 95.20 Mn |
| Mar 31, 2022 | 79.23 Mn |
| Dec 31, 2021 | 34.01 Mn |
| Sep 30, 2021 | 44.70 Mn |
API Access
Savara Cash & Equivalents API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=SVRA&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "cash-and-equivalents", "ticker": "SVRA", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=SVRA&period=max&api_key=YOUR_API_KEY");
const data = await res.json();